EGFR inhibition as a therapy for head and neck squamous cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 17, Issue 10, 2008, Pages 1517-1531

  Loeffler Ragg, Judith ^a   Schwentner, Ilona ^b   Sprinzl, Georg M ^b   Zwierzina, Heinz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

EGFR; HNSCC; Monoclonal antibody; Tryrosine kinase inhibitor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HUMAX EGFR; IMC A 12; IMC A12; K RAS PROTEIN; LAPATINIB; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SULINDAC; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; ZALUTUMUMAB;

ACNE; ALLERGIC REACTION; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASEPTIC MENINGITIS; ASTHENIA; BACTEREMIA; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EPIGLOTTITIS; FATIGUE; FLUSHING; FOLLICULITIS; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERHIDROSIS; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; INOPERABLE CANCER; LOADING DRUG DOSE; LOW DRUG DOSE; METABOLIC DISORDER; MONOTHERAPY; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PAIN; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REPEATED DRUG DOSE; REVIEW; RIGOR; SALVAGE THERAPY; SEBORRHEIC DERMATITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; SKIN TOXICITY; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; TREMOR; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 52949133777     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.10.1517     Document Type: Review

References (104)

1. Sankaranarayanan R, Masuyer E, Swaminathan R, et al. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 1998;18:4779-86
2. Pignon J, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55
3. Morton R, Rugman F, Dorman E, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985;15:283-9
4. Browman G, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 1994;21:311-9
5. Ford A, Grandis J. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003;25:67-73
6. Cohen S, Carpenter G, King LJ. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980;255:4834-42
7. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85
8. Ciardiello E Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74
9. Mendelsohn J, Baselga J. The EGF receptor family as target for cancer therapy. Oncogene 2000;19:6550-65
10. Yarden Y, Shilo B. SnapShot: EGFR signaling pathway. Cell 2007; 131:1018
11. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16
12. Lo H, Hung M. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2007;96(Suppl): 16-20
13. Grandis J, Sok J. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37-46
14. Kalyankrishna S, Grandis J. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72
15. Rogers S, Harrington K Rhys Evans P, et al. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 2005;24:47-69
16. Bei R, Budillon A, Masuelli L, et al. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 2004;204:317-25
17. Ongkeko W, Altuna X. Weisman R, et al. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 2005;124:71-6
18. Santini J, Formento J, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-9
19. Dassonville O, Formento J, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8
20. Ang K Berkey B, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6
21. Rubin Grandis J, Melhem M, Gooding W, et al. Levels of TGF-alpha and EGFR protein in head and neck-squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32
22. Psyrri A, Yu Z, Weinberger P, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11:5856-62
23. Shin D, Ro J, Hong W, Hittelman W. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:3153-9
24. Grandis J, Tweardy D. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84
25. Takes F, Baatenburg de Jong R, Schuuring E, et al. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 1998;18:4793-800
26. Grandis J, Zeng Q, Dreaning S, et al. Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line. Int J Oncol 1998;13:375-8
27. Amador M, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-43
28. Etienne-Grimaldi M, Pereira S, Magné N, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 2065;16:934-41
29. Hynes N, Lane H. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
30. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal and body. Drugs Today (Barc) 2005;41:107-27
31. Baselga J, Pfister D, Cooper M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14
32. Shin D, Donato N, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13
33. Herbst R, Arquette M, Shin D, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87
34. Baselga J, Trigo J, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77
35. Vermorken J, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7
36. Burtness B, Goldwasser M, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:9646-54
37. Vermorken JB, Mesia R, Vega Villegas ME, et al. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5,FU) in the first-line treatment of Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). J Clin Oncol (Mee in Abstracts) 2006;24:5537
38. Sheridan M, O'Dwyer T, Seymour C, et al. Potential indicators of radinsensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997;5:180-6
39. Akimoto T, Hunter N, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-90
40. Balaban N, Moni J, Shannon M, et al. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1996;1314:147-56
41. Harari P, Huang S. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 2001;11:281-9
42. Sartor C. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 2003;13:22-30
43. Saleh M, Raisch K, Stackhouse M, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999;14:451-63
44. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-8
45. Robert F, Ezekiel M, Spencer S, et al. Phase I study of anti-epidermal growth factor receptor antibody ceruximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43
46. Bonner J, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
47. Pfister D, Su Y, Kraus D, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-8
48. Bastholt L, Specht L, Jensen K, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007;85:24-8
49. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54
50. Cohen E, Rosen F. Stadler W, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7
51. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular Phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J Clin Oncol (Meeting Abstracts) 2005;23:5531
52. Cohen E, Kane M, List M, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8418-24
53. Chua D, Wei W, Wong M, et al. Phase II study of gefitinib fi)r the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008;30:863-7
54. Kirby A, A'Hern R. D'Ambrosio C, et al. Gefitinib (ZD1839, Iressa.) as Palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006;94:631-6
55. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25:4880-6
56. Doss HH, Greco FA, Meluch AA, et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network J Clin Oncol (meeting Abstracts) 2006;24:5543
57. Soulieres D, Senzer N, Vokes E, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85
58. Siu L, Soulieres D, Chen E, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25:2178-83
59. Kim ES, Kies MS, Glisson BS, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol (Meeting Abstracts) 2006;24:5521
60. Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:7086-92
61. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007;7:257-68
62. Bourhis J, Harrington K. A phase I, open label study (EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2006;17:576PD
63. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 2006;24:5568
64. Eberhard D, Giaccone G, Johnson B. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94
65. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-46
66. Perez Soler R, Delord J, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56
67. King LJ, Gates R, Stoscheck C, et al. The EGF/TGF alpha receptor in skin. J Invest Dermatol 1990;94:S164-70
68. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10(7):505-10
69. Busam K, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76
70. Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007;25:2184-90
71. Paez J, Jänne P, Lee J, et al. EGFR mutations in lung cancer: correlation with clinical response to gefi tinib therapy. Science 2004;304:1497-500
72. Pao W, Miller V. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68
73. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006;11:190-8
74. Lynch T, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
75. Sordella R, Bell D, Haber D, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7
76. Loeffler Ragg J, Witsch Baumgartner M, Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinom. Eur J Cancer 2006;42:109-11
77. Lee J, Soung Y, Kim S, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-82
78. Cohen E, Lingen M, Martin L, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11:8105-8
79. Chung C, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6
80. Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006;12:6643-51
81. Willmore Payne C, Holden J, Layfield L. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006;19:634-40
82. Temam S, Kawaguchi H, El Naggar A, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25:2164-70
83. Sok J, Coppelli F, Thomas S, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-73
84. Nishikawa R, Ji X, Harmon R, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-31
85. Lievre A, Bachet J, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9
86. Eberhard D, Johnson B, Amler L, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9
87. Anderson J, Irish J, Ngan B. Prevalence of RAS oncogene mutation in head and neck carcinomas. J Otolaryngol 1992;21:321-6
88. Han S, Jeon Y, Lee K, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenet Genomics 2007;17:313-9
89. Buerger H, Gebhardt F, Schmidt H, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854-7
90. Liu W, Innocenti F, Wu M, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005;65:46-53
91. Hirsch F, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18:752-60
92. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specifi c prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003;63:1179-82
93. Erjala K, Sundvall M, Junttila T, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-11
94. Albanell J, Codony Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10
95. Grandis J, Drenning S, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97:4227-32
96. Xi S, Zhang Q, Gooding W, et al. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 2003;63:6763-71
97. Boyle J, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-80
98. Freier K, Bosch F, Flechtenmacher C, et al. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Res 2003;23:3971-7
99. Rodrigo J, Lazo P, Ramos S, et al. MYC amplification in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1996;122:504-7
100. Reed A, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/ INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3
101. Neuchrist C, Erovic B, Handisurya A, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003;25:464-74
102. Phase III trials on the anti-EGFR agents cetuximab, zalutumumab, panitumumab, erlotinib, gefitinib or lapatinib, in primarily advanced HNSCC. Available from: http://www.cancer.gov/clinicaltrials
103. Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-9
104. Reuter C, Morgan M, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007;96:408-16